No results were found for your search. Please adjust your search term or broaden your search criteria.
Still can't find what you are looking for? We can prepare Custom Research for you.
The Aryl Hydrocarbon Receptor (AhR) is a transcription factor that plays a role in the regulation of a variety of physiological processes, including drug metabolism, inflammation, and immune response. It is also a target for drug development in a variety of therapeutic areas, including oncology, immunology, and metabolic diseases.
AhR-targeted drugs are being developed to treat a range of diseases, including cancer, autoimmune diseases, and metabolic disorders. In oncology, AhR-targeted drugs are being developed to target tumor cells and to modulate the immune system to fight cancer. In immunology, AhR-targeted drugs are being developed to modulate the immune system to treat autoimmune diseases. In metabolic diseases, AhR-targeted drugs are being developed to modulate the metabolism of lipids and glucose.
Companies in the AhR market include AbbVie, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Merck, Novartis, Pfizer, and Roche. Show Less Read more
